Physical Therapy vs Medication: Early Inflammatory Arthritis

Research-informed explainer — last updated April 11, 2026

For early inflammatory arthritis — including early rheumatoid arthritis — medication is not optional, but physical therapy is not optional either. The two approaches do different jobs. Disease-modifying drugs (DMARDs) slow or halt the immune attack on your joints; physical therapy preserves and restores the function, strength, and range of motion that the disease has already taken away. Decades of research, including landmark trials and international consensus guidelines, make clear that early, aggressive DMARD treatment is the single most powerful tool for preventing permanent joint damage. But those same guidelines treat exercise and rehabilitation as a required component of care, not a nice-to-have.

This explainer draws on published research from four rheumatologists in the Convene directory: Joan Bathon, M.D., at NewYork-Presbyterian/Columbia, whose work on early RA pharmacotherapy — including the ERA trial and early COMET data — defined the standard of care; Kenneth Saag, MD, at the University of Alabama at Birmingham, who co-authored both the 2016 and 2021 ACR treatment guidelines; Minna Kohler, M.D., at Massachusetts General Hospital, whose research on objective disease assessment and anti-inflammatory drug safety informs monitoring decisions; and Paul Sutej, MD, whose 1991 paper on rehabilitation principles for RA patients remains a foundational reference on the physical therapy side.

What "early" inflammatory arthritis means

Inflammatory arthritis refers to a group of conditions — most commonly rheumatoid arthritis (RA), psoriatic arthritis, and related disorders — where the immune system mistakenly attacks the lining of the joints. This creates inflammation that, if left untreated, damages cartilage and bone over time.

"Early" typically means within the first few months to two years of symptoms. This window matters enormously because the joint damage that accumulates in untreated or undertreated disease is largely irreversible. Once cartilage erodes and bone erodes, physical therapy can help you work around the damage, but it cannot restore what was lost.

The goal of early treatment is to catch the disease before that damage accumulates. Rheumatologists use the phrase "treat to target" — meaning the goal is clinical remission or low disease activity, not just symptom management.

What medications actually do

DMARDs — disease-modifying antirheumatic drugs — are the backbone of inflammatory arthritis treatment. Unlike pain relievers or anti-inflammatory drugs such as ibuprofen, DMARDs change the underlying course of the disease by suppressing or modulating the immune activity driving joint destruction.

The most widely used first-line DMARD is methotrexate. A 2000 landmark randomized trial published in the New England Journal of Medicine compared etanercept (a biologic DMARD) to methotrexate in patients with early active rheumatoid arthritis [1]. Patients treated with etanercept showed faster symptom improvement and less radiographic joint damage progression than those on methotrexate alone — but both groups showed meaningful benefit compared to historical controls. That trial helped establish both that biologics can outpace conventional DMARDs and that early intervention, with either agent, is highly effective.

A 2004 randomized controlled trial published in Arthritis & Rheumatism went further, testing the combination of infliximab (another biologic) plus methotrexate against methotrexate alone in early RA [4]. The combination was superior across clinical, radiographic, and functional measures — patients on combination therapy had significantly less joint damage progression and better physical function at two years. This became one of the foundational arguments for early combination therapy in patients with high-risk disease features.

What physical therapy does

Physical therapy for inflammatory arthritis targets a different problem. Once inflammation is present — even if medication is controlling it — the joint itself may have lost range of motion, the surrounding muscles may have weakened from disuse or pain guarding, and the patient may have developed compensatory movement patterns that create new problems over time.

A 1991 paper on current rehabilitation principles for RA, published in Clinical Orthopaedics and Related Research, outlined the rationale still recognized today: rehabilitation is not salvage after damage occurs, but a continuous program that should be applied throughout the disease course [7]. Range-of-motion exercises preserve joint mobility. Strengthening exercises protect joints by shifting load to muscles rather than cartilage. Aerobic conditioning reduces fatigue — one of the most functionally disabling symptoms of RA — and supports cardiovascular health, which is independently compromised in inflammatory arthritis.

Physical therapists also educate patients on joint protection strategies: how to open jars, lift objects, and perform daily tasks in ways that reduce mechanical stress on inflamed joints.

At a glance

What the guidelines say

Both the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) have issued guidelines making early DMARD treatment a strong recommendation — not a conditional one.

The 2021 ACR Guideline for the Treatment of Rheumatoid Arthritis, published in Arthritis Care & Research, emphasizes a treat-to-target strategy: start a DMARD (typically methotrexate) as soon as the diagnosis is confirmed, reassess every 1–3 months, and escalate therapy if remission or low disease activity has not been achieved [3]. The guideline explicitly frames shared decision-making as central to treatment — it is not a mandate for any single drug, but it is a mandate for early treatment.

The 2022 EULAR recommendations, published in the Annals of the Rheumatic Diseases, are similarly unambiguous about early treatment [2]. They recommend starting a conventional DMARD immediately after diagnosis and adding a biologic or targeted synthetic DMARD if the first strategy fails to reach the target within 3–6 months. Both guidelines acknowledge that non-pharmacologic treatments — exercise, physical therapy, occupational therapy — are important adjuncts, but neither positions them as a substitute for DMARDs.

The 2016 EULAR guidelines, co-authored by Kenneth Saag, made the same case with slightly different language: tight control of disease activity with periodic objective reassessment is the strategy most likely to prevent long-term disability [5].

Why you cannot choose one over the other

This question often comes up in practice — usually from patients who are worried about the side effects of medication, or who have had good experiences with physical therapy for mechanical joint pain (like osteoarthritis). The framing of "PT vs. medication" applies well to osteoarthritis, where exercise is a primary treatment and anti-inflammatories are for symptom management. It does not apply to inflammatory arthritis.

The difference is biology. In inflammatory arthritis, an overactive immune process is actively destroying joint tissue. Physical therapy cannot stop that process. It can help you maintain function while the disease is active and restore function once it is controlled, but it does not address the underlying mechanism.

Conversely, DMARDs can reduce inflammation and slow damage progression but do not rebuild muscle strength, restore range of motion that has been lost, or teach you how to protect your joints during daily activity. Patients who achieve remission on medication but never engage in rehabilitation often remain disabled because of the functional losses that accumulated before or during treatment.

When medication is adjusted or temporarily stopped

Some patients ask whether physical therapy can replace medication during pregnancy, planned surgery, or a drug holiday. The short answer is: it is a bridge, not a substitute. Physical therapy can help maintain function during a short-term treatment gap, but inflammation typically returns or worsens when DMARDs are stopped, and that inflammation means ongoing joint damage risk. Any changes to your medication regimen should be planned with your rheumatologist, not managed through exercise alone.

Topical anti-inflammatories and the monitoring question

Topical NSAIDs (like diclofenac gel) are sometimes used as adjuncts for localized joint pain. A systematic literature review published in The Journal of Rheumatology, with Minna Kohler as a contributor, found that topical NSAIDs in older adults with osteoarthritis carry a different side-effect profile than oral NSAIDs — primarily local skin reactions rather than systemic GI or cardiovascular effects [6]. For patients who cannot tolerate oral anti-inflammatories, topical agents can reduce local joint pain as an adjunct. However, topical agents have no disease-modifying effect in inflammatory arthritis and should not be confused with DMARDs.

Questions to ask your rheumatologist

• How quickly do I need to start a DMARD, and which one is appropriate for my disease severity and risk profile?
• What does remission or low disease activity mean for my specific situation, and how will we measure it?
• Should I be working with a physical therapist now, and how do I find one with experience in inflammatory arthritis?
• If I achieve remission on medication, can I safely taper the drug — and what role does maintaining strength and mobility play in staying in remission?
• Are there situations where physical therapy would change which medication I need, or how aggressively I need to treat?

The bottom line

In early inflammatory arthritis, medication and physical therapy address completely different problems and work best together. DMARDs — started early and titrated to remission — are the only tool proven to slow structural joint destruction, and multiple landmark trials and international guidelines make early treatment a strong recommendation with no close alternatives. Physical therapy preserves and restores function, builds the muscle support that protects damaged joints, and helps you live better with the disease at every stage. Choosing one over the other is not a real option: the evidence supports both, and the guidelines require both.